Table 1

Characteristics of the participants (n = 256)

Age, years, Mean (SD)

47 (SD±11)

Women

48.3 (SD±11)

Men

44.8 (SD±10.1)

(P=0.022)

Civil status, n (%)

Married/cohabitant

184 (72)

Living alone

72 (28)

Education, n (%)

Lower: Compulsory - Secondary school

168 (66)

Higher: After secondary school - University

88 (34)

Occupation, n (%)

Work

106 (42)

Work and part-time retired or on sick leave

46 (18)

No work

103 (40)

Missing data (n = 1)


Age at onset, year, Md (Q1 ; Q3 )

31 (25; 38)

Years since onset of MS symptoms, Md (Q1 ; Q3 )

13 (8; 22)

Course of the disease, n (%)

Relapsing - remitting (RR)

186 (73)

Progressive forms (primary [PP] and secondary progressive [SP])

70 (27)

Disease severity, n (%)

Normal neurological condition, EDSS = 0

26 (10)

Mild, 1.0≤EDSS≤ 3.5

157 (61)

Moderate, 4.0≤ EDSS≤5.5

30 (12)

Severe, 6.0≤ EDSS≤6.5

43 (17)

Medication, n (%)

No pharmacological treatment

54 (21)

Pharmacological treatment

202 (79)

Immune-modulating treatment

144 (56)

β-interferon

91 (36)

glatiramer acetate

33 (13)

natalizumab

20 (8)

For fatigue

32 (13)

modafinil

32(13)

amantadinchlorid

2(0.7)

Antidepressants

46 (18)

Analgesics

61 (24)

Spasmolytical treatment

36 (14)


Flensner et al. BMC Neurology 2011 11:27   doi:10.1186/1471-2377-11-27

Open Data